NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
Clinical Trials
54 trialsNCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07314203 2026-01-02
SOP-XH-IRB
Fujian Medical University
Phase 3 Not yet recruiting
NCT07311408 2025-12-31
SHR-2554
China Medical University, China
Phase 2 Recruiting
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04581473 2025-06-05
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT06485271 2024-07-03
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Changzhi People's Hospital Affiliated to Changzhi Medical College
Recruiting
NCT06415669 2024-05-29
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05853172 2023-05-10
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04609176 2023-04-21
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Peking University
Phase 2 Unknown
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT02711969 2022-07-22
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
Bukwang Pharmaceutical
Phase 1 Completed
NCT03707028 2022-04-11
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Elevar Therapeutics
Phase 1/2 Terminated
NCT05216237 2022-04-11
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT03104283 2022-03-15
Apatinib for the Elderly Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Completed
NCT02764268 2022-03-11
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase NA Completed
NCT05095636 2021-10-27
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT05029453 2021-08-31
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4 Unknown
NCT04934618 2021-06-22
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT03154983 2020-12-09
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Zhongnan Hospital
Phase 2 Unknown
NCT04338438 2020-11-10
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Beijing Friendship Hospital
Phase 2 Completed
NCT04345783 2020-04-14
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT03229096 2019-06-28
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03889626 2019-03-26
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
Fudan University
Phase 3 Unknown
NCT02697838 2018-10-17
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03598348 2018-07-26
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 3 Unknown
NCT03599778 2018-07-26
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
Anhui Provincial Hospital
Phase 1/2 Unknown
NCT02596256 2018-04-17
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
Chinese PLA General Hospital
Phase 2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT03355612 2017-11-28
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02509806 2017-10-09
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
Hebei Medical University
Phase 2/3 Unknown
NCT02510469 2017-10-09
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
Hebei Medical University
Phase 2/3 Unknown
NCT03007446 2017-09-27
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT03219593 2017-09-11
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Unknown
NCT03276156 2017-09-08
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
Zhejiang Cancer Hospital
Phase 1 Unknown
NCT03271073 2017-09-01
A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT03144843 2017-05-09
Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.
Sun Yat-sen University
Phase 2 Unknown
NCT03026881 2017-03-07
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT01512745 2016-10-17
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT02537171 2016-08-02
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 3 Unknown
NCT02529878 2016-07-26
Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase 2 Unknown
NCT02776527 2016-05-20
A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Unknown